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Background: A variety of interventions has been proposed for symptomatology relief in 
primary headaches. Among these, manual trigger points (TrPs) treatment gains popular-
ity, but its effects have not been investigated yet.
Objective: The aim was to establish the effectiveness of manual TrP compared to 
minimal active or no active interventions in terms of frequency, intensity, and duration of 
attacks in adult people with primary headaches.
methods: We searched MEDLINE, COCHRANE, Web Of Science, and PEDro data-
bases up to November 2017 for randomized controlled trials (RCTs). Two independent 
reviewers appraised the risk-of-bias (RoB) and the grading of recommendations, 
assessment, development, and evaluation (GRADE) to evaluate the overall quality of 
evidence.
Results: Seven RCTs that compared manual treatment vs minimal active intervention 
were included: 5 focused on tension-type headache (TTH) and 2 on Migraine (MH); 3 
out of 7 RCTs had high RoB. Combined TTH and MH results show statistically significant 
reduction for all outcomes after treatment compared to controls, but the level of evidence 
was very low. Subgroup analysis showed a statistically significant reduction in attack 
frequency (no. of attacks per month) after treatment in TTH (MD −3.50; 95% CI from 
−4.91 to −2.09; 4 RCTs) and in MH (MD −1.92; 95% CI from −3.03 to −0.80; 2 RCTs). 
Pain intensity (0–100 scale) was reduced in TTH (MD −12.83; 95% CI from −19.49 to 
−6.17; 4 RCTs) and in MH (MD −13.60; 95% CI from −19.54 to −7.66; 2RCTs). Duration 
of attacks (hours) was reduced in TTH (MD −0.51; 95% CI from −0.97 to −0.04; 2 RCTs) 
and in MH (MD −10.68; 95% CI from −14.41 to −6.95; 1 RCT).
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conclusion: Manual TrPs treatment of head and neck muscles may reduce frequency, 
intensity, and duration of attacks in TTH and MH, but the quality of evidence according 
to GRADE approach was very low for the presence of few studies, high RoB, and impre-
cision of results.
Keywords: migraine disorders, tension-type headache, cluster headache, trigger points, myofascial pain 
syndromes, physical therapy specialty
iNtRODUctiON
Headaches are disabling disorders that decrease the health-
related quality of life. The mean global annual prevalence of 
headaches in adults is around 46% (1), while in Europe the 
gender adjusted 1-year prevalence for any type of headache is 
79% (2) with an estimated economic burden of €173 billion 
yearly among adults aged 18–65 years (3). As in other European 
countries, headaches in Italy are highly prevalent and associated 
with significant personal impact and important implications 
for health policy (4). Therapeutic management option is rep-
resented by pharmacological or non-pharmacological interven-
tions (5). Pharmacological treatments are considered the main 
interventions even though the elevated frequency of attacks 
increases the risk of drugs’ abuse (6). Accordingly, the use of 
non-pharmacological treatments in the management of primary 
headaches has the aim of reducing the drugs’ consumption, their 
side effects, and the interaction with the other drugs used for 
comorbidities (7–9). The recommendation of the European 
Federation of Neurological Societies guideline indicates that 
the use of non-pharmacologic therapies, having less side effects 
than pharmacological therapies (10, 11) may constitute a valid 
therapeutic option for headaches sufferers, despite their limited 
scientific basis (12), and the lack of research on the effectiveness 
of physical therapy treatments.
Tension-type (TTH), migraine (MH), and cluster headache 
(CH) are considered the three most prevalent primary headaches 
according to the classification proposed by the International 
Headache Society (13) that established the clinical criteria use-
ful in the discrimination of headache’s attacks. Hence, distinct 
and specific etiopathological models have been proposed for 
TTH (14, 15) and MH (16) despite this is a still disputed aspect. 
In fact, although the IHS classification has been recognized as the 
most important of the past years (17) some patients with head-
ache may present with overlapping clinical features that makes it 
difficult to correctly classify them, especially in the case of TTH 
and MH (18). The concept of a continuum spectrum between 
these disorders has been proposed to overcome this taxonomic 
problem (19) and since, its validity has been debated in the past 
decades (20–22) as the clinical characteristics of patients in both 
Abbreviations: CTTH, chronic tension type headache; ETTH, episodic tension 
type headache; FETTH, frequent episodic tension type headache; MH, migraine; 
CH, cluster headache; TG, treatment group; CG, control group; PG, placebo 
group; MCIDs, minimal clinical important difference; PIR, post isometric relaxa-
tion; CRAC, contract relax antagonist contraction; DT/IDT-MFR, direct/indirect 
myofascial release; SSTM, specific soft tissue mobilization; PRT, positional release 
therapy; TNC, trigeminal nucleus caudalis.
TTH and MH groups come across with more similarities than 
differences. Patients may share demographic characteristics for 
specific age groups and respond positively to similar treatments 
(23); also most triggering factors (e.g., stress) are shared between 
MH and TTH (24, 25). Moreover, alterations like decreased gray 
matter in brain areas associated with pain transmission (anterior 
cingulate, insular cortices, and the dorsal rostral pons) are com-
mon in patients with TTH and MH (26, 27). In the so-called 
continuum model, MH and TTH represent different points on 
a single continuum of severity, with migraine falling at the more 
severe end of the symptom spectrum (28–30). Therefore, the 
different clinical headache expressions are considered the result 
of the different extent of sensitization occurring at the first- and 
second-order neurons of the trigeminal nucleus caudalis (TNC) 
induced by alterations of the trigeminal nerve (30).
Despite the neurophysiologic influence of trigger points 
(TrPs) on pain mechanisms seems attributable to their action 
as nociceptive sources (31, 32), the pathophysiology of TrPs on 
pain still needs to be elucidated (33, 34). Patients with chronic 
TTH and MH have a greater number of TrPs compared to 
healthy subjects (35–37); the higher number of TrPs correlates 
with the severity and the duration of TTH attacks (38), but not 
in MH attacks (36). Furthermore, even though the pain of MH is 
predominantly associated with the activation of the trigeminal-
vascular system (16), TrPs can be seen as additional stimuli 
that may contribute to start a migraine attack (37, 39, 40) and 
the inhibition of TrPs by mean of anesthetic injections led to a 
decrease in the frequency and severity of migraine attacks (41). 
The same intervention also promoted the reduction of attacks’ 
frequency and intensity in a case series of patients with CH (42). 
However, it is unclear whether the TrPs may have a pathogenetic 
role (14) or constitute a precipitating factor of separate clinical 
conditions (15). In both cases, the TrPs are involved in the patho-
physiology of primary headaches as a peripheral mechanism able 
to sensitize the TNC (43, 44). Whatever the influence of TrPs on 
the pathophysiology of TrPS will be, these findings suggest that 
the TrPs treatment could be useful to prevent or decrease the 
extent of primary headaches.
Myofascial TrPs treatment is usually pursued with invasive 
(dry or wet needling) or non-invasive techniques (manual treat-
ment or low-level laser therapy) (32) that, according to the most 
accepted hypothesis (33), are thought to reduce the ischemia-
related nociception activated by the contracture of a small por-
tion of muscle and, consequently, the degree of sensitization of 
TNC. Among the manual treatment of TrPs several techniques 
have been proposed that act directly or indirectly on the TrPs. 
Techniques that are thought to reduce the muscle contraction 
with mechanical forces (compression, distraction) acting directly 
3
Falsiroli Maistrello et al. TrPs Manual Treatment in Primary Headaches
Frontiers in Neurology | www.frontiersin.org April 2018 | Volume 9 | Article 254
on the TrPs site or the surrounding tissues are ischemic compres-
sion (45), myofascial release (46), acupressure (47), and specific 
soft tissues mobilization techniques (48). Indirect techniques, 
such as muscle energy (49), positional release (50), and strain–
counterstrain techniques (51) are thought to reduce muscle 
contraction for neurophysiological mechanisms regulating the 
muscle tone.
Several reviews have considered the efficacy of various 
inter ventions used in physiotherapy to treat primary head-
aches, including many manual therapies, multimodal and 
manipulative approaches, but the results were usually obtained 
grouping heterogeneous or combined treatment and consider-
ing primary headaches as separate entities (5, 9, 52–56). To our 
knowledge, the effectiveness of neither manual TrPs treatment 
in case of primary headaches has not been investigated yet 
nor it has been established considering patients with differ-
ent primary headaches (MH, TTH) an homogeneous patient 
group, as proposed by the continuum severity model. The 
main purpose of this review was to establish the effectiveness 
of manual treatment of TrPs in reducing frequency, intensity, 
and duration of primary headaches. We will also investigate 
additional positive or negative effects of the manual treatment 
of TrPs and whether there is a manual technique or a treatment 
dosage to prefer.
metHODS
We conducted this systematic review following the preferred 
reporting items for systematic reviews and meta-analyses state-
ment (57) and the Cochrane handbook for systematic reviews of 
interventions (58). The protocol of the review was registered in 
PROSPERO, an international prospective register of systematic 
reviews (registration code CRD42016046374) (59).
eligibility criteria
Types of Studies
Randomized controlled trials (RCTs) written in English, Italian, 
or Spanish.
Types of Participants
Participants included in the studies were adult subjects (age 
>18 years) with primary headaches (TTH, MH, CH) diagnosed 
using the International Classification of Headache Disorders 
criteria (13).
Types of Interventions
Any direct or indirect manual treatment targeting the TrPs, 
such as compression techniques, muscle energy techniques, 
myofascial techniques, acupressure, soft tissues techniques, or 
positional release techniques. Studies that proposed different 
approaches were considered only if the manual TrPs treatment 
was proposed as the only treatment in one of the intervention 
groups (60). Studies without manual TrPs treatment or refer-
ring to any pharmacological or injection treatment, spinal 
manipulation, and exercise without manual TrPs treatment 
were excluded.
Types of Comparators
Acceptable comparators were any type of minimal active inter-
vention (placebo, sham treatment, routine medication, or wait 
list supported with routine medication) or no active intervention 
(wait list or no treatment).
Types of Outcomes
We considered as primary outcomes the variation of frequency of 
the attacks (number of attacks per month), the intensity of attacks 
[valuated with the 0–100 mm visual analog scale (VAS) or 0–10 
numerical pain intensity scale—NPRS or similar scales], and 
duration of attacks (number of hours per attack). Secondarily, we 
also considered quality of life, medicine consumption, effects on 
TrPs, and any adverse event, such as dizziness, bruising, muscle 
stiffness, and post-treatment pain. Each outcome was considered 
in the period after the intervention (run-out period).
Search Strategy
The literature search was performed by two independent 
authors (FML and ZM) on MEDLINE, COCHRANE, Web 
Of Science, and PEDro databases, without the adoption of 
limits or filters. Relevant reviews were consulted for addi-
tional studies to consider. Last search was done on November 
17, 2017. The full search strategy through all databases 
is reported in Appendix S1 in Supplementary Material.
Study Selection
Two independent authors (FML and ZM) screened the record by 
title and abstract applying the eligibility criteria. At the end of the 
screening process, full-text articles were retrieved and assessed 
for their eligibility in the qualitative and/or quantitative synthesis. 
Any disagreement was resolved by consensus, otherwise a third 
author (GT) made the final choice. The inter-reviewers agree-
ment of the eligibility process before consensus was expressed 
using the Cohen’s kappa.
Data collection
Two authors (FML and ZM) independently collected informa-
tion from the included trials by an ad hoc extraction form. The 
extracted data were inserted into a pre-formatted table for studies’ 
characteristics, such as author, year, design, country, headache 
diagnosis, sample size calculation, number of participants 
recruited, drop-outs, intervention (treatment and control), 
duration, follow-up, outcomes, and measure unit. Disagreements 
between reviewers were resolved by consensus or if no agreement 
could be reached, a third author (GT) was consulted.
Risk of Bias (RoB) assessment
The internal validity on the included studies was assessed with the 
Cochrane RoB tool (58). The following domains were appraised: 
selection bias (random sequence generation and allocation 
concealment), performance bias (blinding of participants and 
personnel), detection bias (blinding of outcome assessment), 
attrition bias (incomplete outcome data), and reporting bias 
(selective reporting) (58). Each domain could be classified 
as “high,” “low,” or “unclear” RoB if the study did not provide 
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sufficient information to judge. Two reviewers (FML and ZM) 
independently assessed the above-mentioned domains of RoB. 
Any disagreement was resolved by consensus or if no consensus 
was obtained a third reviewer (GT) made the final choice. Strength 
of inter-raters agreement before consensus was expressed using 
the Cohen’s kappa.
analysis and Synthesis of Results
We evaluated the treatment effects for dichotomized outcomes 
using the risk ratio (RR), and for continuous outcomes using 
the pooled mean difference (MD). The variance was expressed 
with 95% confidence intervals (95% CI). The outcome meas-
ures from the individual trials were combined through meta- 
analysis were possible using random-effects models described by 
DerSimonian and Laird (61) because a certain degree of hetero-
geneity of population and treatments would be expected among 
interventions of trials. If any planned outcome was not reported 
quantitatively, a comprehensive description was reported. Since 
similar scales with different ranges were used to measure the 
intensity of pain (e.g., VAS 0–10 and VAS 0–100), we linearly 
transformed each scale into a 0–100 scale (correcting the SDs 
accordingly) in order to directly compare the pain scales. This 
method proved to be suitable for being able to directly compare 
different pain scales (62).
For the meta-analyses, we entered the mean values and SDs 
measured after the intervention (run-out). If SDs were not 
reported, we calculated it from SEs. All frequencies of attacks 
were normalized in attacks per month (mean and SD).
The units of randomization and analysis in the included trials 
were the individual participants. When a trial presented multiple 
comparisons, in order to overcome a unit-of-analysis error we 
used a suggested method (63) that consisted in splitting the 
participants of the intervention (64) or the comparison groups 
(65) in two or more groups with smaller sample size, but equal 
means and SDs in order to avoid the loss of data that could have 
occurred when only a single pair of interventions is chosen or a 
treatment group (TG) is deleted.
We analyzed heterogeneity by means of the I2 statistic and 
the Chi2 test. A P-value of less than 0.1 indicated a statistically 
significant heterogeneity for the Chi2 test (66). The percentage 
of I2 represented the degree of heterogeneity: percentages of 
25, 50, and 75% indicated a low, moderate, and high degree of 
heterogeneity, respectively (66). If a study did not provide usable 
summary measures for an outcome it was included in the review, 
but excluded from the meta-analysis, e.g., Lawler and Cameron 
(67). For included studies, the number of lost to follow-up in each 
group and reasons for attrition were recorded. For missing data, 
similarity of group was evaluated, then the corresponding authors 
of included studies were contacted (e.g., emailing or writing to 
corresponding author/s) and if no information were provided, 
we conducted analyses using only available data (i.e., we did not 
impute missing data) (63).
We pooled studies through a subgroup analysis according to 
the type of specific headache. Furthermore, sensitivity analyses 
for RoB assessment were planned in case of sufficient numbers of 
studies in each pairwise comparison.
The software used was Cochrane Review Manager Version 
5.3 (68).
Level of evidence
To evaluate the overall quality of evidence, we used the grading 
of recommendations assessment, development and evaluation 
approach (GRADE), for the main outcome based on the method-
ological quality of included trials (69). The highest quality rating 
is for evidence based on RCTs with a low RoB. However, it is pos-
sible for authors to downgrade this level of evidence to moderate, 
low, or even very low. The quality of evidence depends on the 
presence of five factors: study limitation (RoB), indirectness of 
evidence, unexplained heterogeneity or inconsistency of results, 
imprecision of results, and high probability of publication bias 
(70). For the RoB factor, the evidence was arbitrary downgraded 
by one level when two criteria were judged as high or unclear, 
and by two levels when more than two criteria displayed high or 
unclear risk. The software used was GRADEPro GDT (71).
Two authors (FML and ZM) independently assessed the qual-
ity of evidence and the RoB. In case of doubt, another reviewer 
(GT) was consulted for the final choice. Strength of inter-raters 




We identified 914 records through databases searching and 
8 from additional references (52, 53, 72, 73). After removal 
of duplicates, a total of 390 records were selected for screen-
ing. We excluded 356 records after reading title and abstract. 
Of the 34 remaining articles assessed, only seven were con-
sidered eligible (Figure  1) (60, 64, 65, 67, 74–76). The inter-
reviewer agreement regarding study eligibility was moderate 
with a kappa of 0.69.
General Study characteristics
All studies were RCTs; five trials concerned TTH (60, 64, 65, 
74, 75) and two MH (67, 76). No studies were found concerning 
CH (Table 1).
The pooled population was of 316 subjects (mean age 
39.0 ± 11.6 years) with a significant majority of female subjects 
(251 F, P < 0.05). A mean of 45.1 (±9.2) patients were randomized 
in each trial. One RCT concerned chronic TTH (75, 77), one 
concerned episodic TTH (65), two considered both frequent-
episodic TTH and chronic TTH (60, 64), one RCT concerned 
MH with and without Aura (67), and two RCTs concerned 
undefined/unclassified TTH (74) and MH (76).
The TTH subgroup consisted of 225 subjects (71% of the 
whole population; mean age 38.9 ± 9.8 years) with a significant 
majority of female subjects (188 F, P < 0.05). One hundred and 
twenty-six subjects had chronic TTH (60, 64, 74, 75, 77), 55 had 
frequent-episodic TTH (60, 64), and 47 had episodic TTH (65).
The MH subgroup consisted of 91 subjects (29% of the whole 
population; mean age 39.3 ±  13.5 years) with a not significant 
FiGURe 1 | Studies selection flow diagram.
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majority of female subjects (63 F, P = 0.41). Sixty subjects had 
MH without Aura (67, 76) and 31 had MH with Aura (67, 76).
Headaches were diagnosed using the International Classi-
fication of Headache Disorders criteria (13). In five trials (60, 64, 
65, 74, 76), the diagnosis was done by a neurologist while 
in two trials the diagnosis was made either on the score of 
the Headache History Inventory (67) or by a general practi-
tioner (75).




Ha diagnosis, No. of subjects 
recruited, drop-out, sample size 
calculation (primary outcome), 






CTTH/ETTH (diagnosis by 
neurologist) N = 63 (36 F,  
CTTH = 9, ETTH = 47)
Drop-out: 7
Sample size calculation: no




All groups: two 60′ sessions  
per week for 12 weeks.
TG1: treatment with DT-MFR 
protocol.
TG2: treatment with IDT-MFR 
protocol.
CG: slow soft stroking with finger 
pads all over the head in the  
same area of MFR techniques.
Duration 16 weeks:
 – 4 weeks baseline
 – 12 weeks 
treatment
Run-out:
 – 4 weeks post 
treatment
Self reported daily headache diary
 – Frequency: no. of days with HA  
per 4 weeks
 – Intensity and duration: not assessed
Berggreen (75), 
RCT, Denmark




Sample size calculation: yes (pain)
Trial arm: N (mean age ± SD)
TG: 19 (38.8 ± 13.7)
CG: 16 (42.3 ± 10.2)
TG: one session of TrPs treatment 




 – 4 weeks baseline
 – 10 weeks 
treatment
Run out:
 – 4 weeks post 
treatment
Self reported daily headache diary
 – Intensity: 100 mm VAS
 – Frequency and duration: not assessed
Other outcomes:
 – Inconvenience of the pain: 100 mm VAS
 – Medicine consumption
 – Number of TrPs
 – Multidimensional pain: MPQ Mc gill pain 
questionnaire;




CTTH/FETTH (diagnosis  
by neurologist)
N = 100 (78 F, CTTH = 41, 
FETTH = 56)
Drop-out: 3
Sample size calculation: yes (HIT-6)





All groups: Six 15′ sessions: 2 in  
the first week, 2 in the second  
week, and 1 each in the third  
and the fourth week.
TG1: 3′ of soft tissue techniques  
in each pair of craniocervical region 
muscles.
TG2a: neural mobilization techniques
TG3a: treatment 1 and 2 combined
PG: sham massage
Duration 6 weeks:
 – 2 weeks baseline
 – 4 weeks treatment
Run out:
 – 2 weeks post 
treatment
Follow-up:
 – 4 weeks after 
treatment
Self reported daily headache diary
 – Frequency of attack: no. of days  
with HA in 2 weeks
 – Intensity: 0–10 mm VAS
 – Duration: not assessed
Other outcomes:
 – Pressure pain treshold




CTTH (diagnosis by neurologist)
N = 30 (28 F)
No drop-out.
Sample size calculation:  
estimated from previous study; 
primary outcome not spec.
Trial arm: N (mean age ± SD)
TG: 15 (37.7 ± 8.6)
CG: 15 (36.3 ± 7.5)
TG: five sessions (from 60′ to 100′)  
of positional release therapy (PRT)  
in 2 weeks.
CG: routine medications with  
NSAIDs as abortive drugs and  
TCAs as prophilactic drugs
Duration 4 weeks:
 – 2 weeks baseline
 – 2 weeks treatment
Run-out:
 – 2 weeks post 
treatment
Self reported daily headache diary
 – Frequency of attack: no. of days  
with HA in 2 weeks
 – Intensity: 10 point NPI
 – Duration: number of hours per attack.
Other outcomes:
 – Tablet count: no. of pain rescue tablet used
 – TrPs sensitivity measured by digital  
force gage and numeric pain intensity
Ghanbari (76), 
RCT, Iran
MH (diagnosis by neurologist)
N = 44 (24 F)
No drop-out
Sample size calculation: no
Trial arm: N (mean age)
TG: 22 (38.7)
CG: 22 (35.9)
TG: five 90′ sessions of PRT in 
2 weeks + routine medications  
with NSAIDs, nortriptyline, 
propranolol, and depakine.
CG: routine medications with 
NSAIDs, nortriptyline, propranolol  
and depakine
Duration 4 weeks:
 – 2 weeks baseline
 – 2 weeks treatment
Run out:
 – 4 weeks post 
treatment
Follow-up:
 – 2 and 4 months 
post treatment
Self reported daily headache diary
 – Frequency of attack: no. of days with HA
 – Intensity: 0–5 pain scale
 – Duration: number of hours per attack.
Other outcomes:
 – Tablet count: no. of pain rescue tablet used
 – TrPs sensitivity measured by digital force gage
 – Cervical range of motion by clinical  
goniometer (flexion, extension,  
rotation, lateral flection)
Lawler (67), RCT, 
New Zealand
MH (diagnosis by questionnaire)
N = 48 (40 F)
Drop-out: 4
Sample size calculation: no
Trial arm: N (mean age ± SD)
GT: 23 (41.3 ± 13.5)
GC: 21 (41.3 ± 13.5)
GT: one 45′ sessions every week  
for 6 weeks. Trigger-point treatment 
of the back, shoulders, neck, and 
head with myofascial release (3 min), 




 – 4 wk baseline
 – 6 wk treatment.
Run out:
 – 3 wk post 
treatment
Self reported daily headache diary
 – Frequency of attack: no. of days with HA
 – Intensity: 0–5 pain scale
 – Duration: not assessed.
Other outcomes:
 – Drugs consumption
 – Effect after treatment on heart rate,  
state anxiety, and salivary cortisol.
 – Stress and coping: perceived stress scale.
 – State anxiety: STAI-sf state anxiety scale
(Continued )
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Ha diagnosis, No. of subjects 
recruited, drop-out, sample size 
calculation (primary outcome), 






CTTH/FETTH (diagnosis  
by neurologist)
N = 62 (48 F, CTTH = 30, 
FETTH = 26)
Drop-out: 6
Sample size calculation:  
yes (frequency)




All groups: two 45′ session  
per week for 6 weeks.
TG: manual TrPs treatment 
composed by 15′ of myofascial 
release, 20′ of trigger point release 
massage TRP, 10′ PIR
PG: detuned ultrasound in specified 
head and neck muscle areas
CG: no treatment
Duration 10 weeks:
 – 4 wk baseline
 – 6 wk treatment
Run out:
 – 4 wk post 
treatment
Self reported daily headache diary
 – Frequency of attack: no. of days  
with HA in 4 weeks
 – Intensity: 100 mm VAS
 – Duration: number of hours per attack.
Other outcomes:
 – Use of pain medication
 – Perceived clinical change
 – Pressure pain treshold
 – Quality of life: headache disability  
inventory and headache impact  
test-6 HIT-6
RCT, randomized controlled trial; F, female; wk, weeks; CTTH, chronic tension type headache; ETTH, episodic tension type headache; FETTH, frequent episodic tension type 
headache; MH, migraine; TG, treatment group; CG, control group; PG, placebo group; VAS, visual analog scale; NPI, numeric pain index; HA, headache; wk, weeks; TrPs, trigger 
points.
aResults from these groups were not included into quantitative analysis.
taBLe 1 | Continued
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All the selected studies compared manual treatment versus 
minimal active treatment: placebo (64), sham massage (60, 65), 
routine medication supported with pharmacological prophilactic 
treatment (74), and wait list supported with routine medication 
(64, 67, 75, 76).
treatment and Sessions
The duration of intervention and the number of treatments 
ranged from 5 sessions in 2 weeks to 24 sessions in 12 weeks with 
an average number of 2 sessions per week; the run-out/follow-
up period varied from a minimum of 2 weeks to a maximum of 
4 months after the end of treatment. The duration of the single 
session ranged from 15 to 100′.
The treatments proposed across all studies were heterogene-
ous: ischemic compression, myofascial release, muscle energy, 
soft tissue treatment, and positional release (Table 2).
Stretching was often used as warm-up and cool-down tech-
nique. The muscles mainly treated were the upper trapezius, the 
sternocleidomastoid, and the suboccipitals; secondarily, other 
neck or head muscles were treated (Table 3).
RoB within Studies
None of the studies had a low RoB for all methodological items, 
while 3 out of 7 studies had more than one high RoB domain 
(64, 65, 67). Three RCTs had low risk in allocation concealment 
(60, 64, 75). As we expected for manual interventions, the blind-
ing of participants and providers was always unachievable while 
blinding of assessors was adequately reported only in 2 out of 7 
studies (60, 65). One RCT had high risk for incomplete outcome 
data because some patients did not maintain headache diaries as 
advised (65). One RCT had high risk in selective reporting because 
primary data about intensity were not provided (67) (Figures 2 
and 3). The agreement between reviewers for individual domains 
of the Cochrane RoB tool was moderate (k = 0.72). Consensus 
was always achieved between the pair of initial reviewers.
Synthesis of the Results
For primary outcome (frequency, intensity, and duration), the 
original measures extracted in each trial are reported in Table 4.
The summary of findings for each outcome in TTH and 
MH and the quality of assessment are reported in Table  5. 
taBLe 2 | Classification of the different TrPs manual treatment techniques.





















Ajimsha (65) TTH X
Berggreen (75) TTH X
Ferragut-Garcías (60) TTH X
Ghanbari (74) TTH X
Moraska (64) TTH X X X
Ghanbari (76) MH X
Lawler (67) MH X X X
TTH, tension type headache; MH, migraine; PIR, post isometric relaxation; CRAC, contract relax antagonist contraction; DT/IDT-MFR, direct/indirect myofascial release; SSTM, 
specific soft tissue mobilization; PRT, positional release therapy.




























































































































































Ajimsha (65) TTH X X X X
Berggreen (75) TTH X X X X X X X X X X X X
Ferragut-Garcías (60) TTH X X X X X
Ghanbari (74) TTH X X X X X
Moraska (64) TTH X X X
Ghanbari (76) MH X X X X X
Lawler (67) MH X X X X X X
TTH, tension type headache; MH, migraine.
FiGURe 2 | Risk of bias (RoB) graph: review authors’ judgments about each RoB item presented as percentages across all included studies.
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The comparisons of interventions listed by outcome for both 
TTH and MH are reported in Appendix S2 in Supplementary 
Material.
Meta-analyses of the pooled results with separated analyses of 
TTH and MH as subgroups are shown for frequency (Figure 4), 
intensity (Figure 5), and duration (Figure 6). Sensitivity analyses 
for RoB assessment were not conducted due to the insufficient 
numbers of studies in each pairwise comparison.
TrPs Manual Treatment vs Minimal Active 
Intervention on TTH and MH Combined
Frequency
A total of six trials (277 subjects) assessed the frequency of 
attacks as number of attacks per month; three trials had high 
RoB (64, 65, 67) and three had low RoB (60, 74, 76). The analysis 
of combined results indicated a statistically significant reduction 
in frequency of attacks per month after treatment favored the 
experimental group compared to control, with a mean reduction 
of 3.05 attacks/month (MD −3.05; 95% CI from −4.11 to −2.00; 
P < 0.01; I2 = 64%; see Figure 4).
Intensity
A total of six trials (256 subjects) assessed the intensity of pain 
using different scales (0–100) VAS (64, 75), 0–10 VAS/NPI 
(numeric pain index) (60, 74), 0–5 pain scale (76); only five trials 
were included into the quantitative analysis for this outcome due 
to missing original data from one study (67), although we tried 
to contact the authors. We found one trial with high RoB (64), 
while four trials had low RoB (60, 74–76). Analysis of combined 
results (referred to a normalized 0–100 scale) showed a significant 
reduction of intensity of attacks in the experimental group (MD 
−12.93; 95% CI from −18.70 to −7.16; P < 0.001; I2 = 90%; see 
Figure 5).
Duration
A total of three trials (130 subjects) assessed the duration of attacks; 
one had high RoB (64) and two had low RoB (74, 76). A mean 
reduction of 1.69 h per attack (MD −1.69; 95% CI from −2.93 to 
−0.46; P < 0.01; I2 = 91%; see Figure 6) favored the experimental 
group compared to control. A greater reduction was found in 
the trial concerning MH that compared the routine medication 
supported with the intervention versus routine medication alone 
FiGURe 3 | Risk of bias (RoB) summary: review authors’ judgments about 
each RoB item for each included study.
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with a mean reduction of 10.68 h per attacks (MD −10.68; 95% 
CI from −14.41 to −6.95; P < 0.001; see Figure 6).
Subgroup Analysis: Treatment Effects on TTH
Frequency
Four trials (189 subjects) of which two had high RoB (64, 65) 
and two had low risk (60, 74) which assessed the frequency of 
attacks. Analysis of combined results indicated a statistically 
significant reduction in frequency of attacks after treatment in the 
intervention group compared to control with a mean reduction 
of 3.50 attacks/month (MD −3.50; 95% CI from −4.91 to −2.09; 
P < 0.001; I2 72%, see Figure 4).
Intensity
Four trials (168 subjects), three with low RoB (60, 74, 75) and 
one with high RoB (64) assessed intensity of pain using different 
scales [0–100 VAS (64, 75), 0–10 VAS/NPI (60, 74)]. The com-
bined results (referred to a normalized 0–100 scale) indicated 
a statistically significant reduction in intensity of attacks after 
treatment in the intervention group compared to control group 
(CG) (MD −12.83; 95% CI from −19.49 to −6.17; P  <  0.001; 
I2 = 92%, see Figure 5).
Duration
Two trials (86 subjects), one with high RoB (64) and one with 
low RoB (74) assessed the duration of attacks measured in hours. 
Analysis of combined results indicated a small reduction in dura-
tion of attacks after treatment in the intervention group compared 
CG with a mean reduction of 0.51 h per attacks (MD −0.51; 95% 
CI from −0.97 to −0.04; P = 0.03; I2 = 54%; see Figure 6).
Subgroup Analysis: Treatment Effects on MH
Frequency
Two trials (88 subjects), one with high RoB (67) and one with 
low RoB (76) assessed the frequency of attacks. A statistically 
significant reduction in frequency of attacks after treatment was 
observed in the intervention group with a mean reduction of 
1.92 attacks/month (MD −1.92; 95% CI from −3.03 to −0.80; 
P < 0.001; I2 = 0%; see Figure 4).
Intensity
The same two trials (88 subjects) assessed the intensity of pain 
(0–5 pain scale). Lawler and Cameron (67) reported no significant 
group × time interaction effect revealed by the repeated measures 
ANOVA of changes from baseline to follow-up [F(1, 42) = 0.82, ns; 
d  =  0.11]; although we tried to contact the authors, we could 
not include these values in the meta-analysis as original data 
were unavailable (67). The results of the second trial (referred 
to a normalized 0–100 scale) indicated a statistically significant 
reduction in pain intensity (MD −13.60; 95% CI from −19.54 to 
−7.66; P < 0.001; see Figure 5).
Duration
Only one trial (44 subjects) with low RoB (76) reported a statisti-
cally significant reduction in duration of attacks after treatment 
in the intervention with a mean reduction of 10.68 h per attacks 
(MD −10.68; 95% CI from −14.41 to −6.95; P  <  0.001; see 
Figure 6).
Additional Treatment Effects on TTH and MH
Number of Active TrPs
Number of Active TrPs in TTH, one RCT reported a significant 
decrease in the number of active TrPs in patients treated with 
ischemic compression (75).
Pressure Pain Threshold (PTT) and TrPs Sensitivity
Pressure pain threshold and TrPs sensitivity in TTH, two RCTs 
reported the increase of the PPT in treated muscles only in 
patients manually treated (P < 0.01) (60, 64); one RCT reported 
a significant reduction for sensitivity of TrPs only in the TG after 
intervention (P < 0.01) and at follow-up (P = 0.015) in TTH (74). 
The same results on TrPs sensitivity were reported in one RCT 
regarding MH (76).
Tablet Count and Medicine Consumption
Tablet count and medicine consumption in TTH, one RCT 
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FiGURe 4 | Forest plot of comparison for frequency (no. of attacks per month) compared with minimal active intervention in TTH (top) and MH (bottom). 
Abbreviations: TTH, tension-type headache; MH, Migraine; CI, confidence interval.
FiGURe 5 | Forest plot of comparison for pain intensity (0–100 scale) compared with minimal active intervention in TTH (top) and MH (bottom). Abbreviations:  
TTH, tension-type headache; CI, confidence interval; MH, Migraine.
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phase (P < 0.01), but the result persisted only in manual TG after 
2 weeks follow-up (p < 0.01) (74). A second study reported a not 
significant reduction of drug’s use only in the TG (P = 0.46) (75) 
while in a third study, no significant TG differences have been 
measured (64). In MH, one RCT reported a significant reduc-
tion in tablet count in both treatment (receiving manual PRT 
FiGURe 6 | Forest plot of comparison for attacks duration (hours) compared with minimal active intervention in TTH (top) and MH (bottom). Abbreviations:  
TTH, tension-type headache; MH, Migraine; CI, confidence interval.
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and medical therapy) and CG (receiving only medical therapy); 
differences between groups at various follow-up were always 
significant (P < 0.001) (76).
McGill Pain Questionnaire and Quality of Life (SF36)
In TTH, one study reported not significant differences between 
manual TG and control (75).
Headache Disability Inventory (HDI), Headache Impact 
Test-6 (HIT-6), and Perceived Clinical Change
In TTH, one study reported a significant decrease in HDI 
scores only in manual TG (P <  0.001) (64). Other two studies 
reported a significant group × time interaction in HIT-6 scores; 
Moraska et  al. (64) detected effects over time for both manual 
treatment and placebo group (P’s  <  0.01) but not in the CG 
(P = 0.52); Ferragut-Garcias et al. (60) detected effects over time 
for all manual TGs (P’s < 0.001) and CG (P < 0.05) compared 
to baseline. Regarding the perceived clinical change, greater pain 
reduction was observed for manual TG compared to placebo or 
CGs (P < 0.01) (64).
Quality and Quantity of Sleep and Stress and Coping (PSS)
Quality and quantity of sleep and stress and coping in MH the 
TG displayed a significant improvement of sleep quality, but not 
of the total amount of sleeping hours (67); in the same study, TG 
displayed no significant change in stress and coping levels during 
both treatment and at follow-up [state trait anxiety inventory scale 
(STAI) and perceived stress scale (PSS)]; otherwise a significant 
deterioration of these outcomes was found only in the CG (67).
Cervical ROM
In MH, one study reported a significant increase of cervical rota-
tion in both experimental and CGs, but flexion, extension, and 
side bend increased only in experimental group after 4 months 
of follow-up (all P’s < 0.001) (76).
DiScUSSiON
The present manuscript aimed at establishing the effectiveness 
of the TrPs manual treatment in reducing the frequency, inten-
sity, and duration of attacks of primary headaches in adults. 
In order to explore this goal the authors’ agreement in perform-
ing articles selection and RoB assessment was moderate (Cohen’s 
k ranged from 0.69 to 0.72), supporting the methodological 
validity of the research.
The quality of the level of evidence ranged from low to very 
low in favor of manual TrPs treatment compared to minimal 
active intervention in the reduction of the frequency, intensity, 
and duration of the attacks in the patients with TTH and MH 
measured in the run-out period after intervention. Further 
findings having very low quality of the evidence were a greater 
reduction of frequency of attacks in patients with TTH and of 
the duration of attacks in the MH subgroup, while the intensity 
of attacks was similarly reduced in both subgroups.
The different extent of efficacy of the TrP treatment on the 
primary headaches considered either as separated entities or 
according to the continuum model needs to be substantiated in 
light of the most accepted hypotheses on the TrP induced pain. 
The integrated TrP hypothesis (33) proposed that a muscle over-
load causes ischemia and hypoxia in the muscle tissue leading to 
a cascade of biochemical events that finally ends in sarcomere 
contraction (e.g., a TrP) and produces nociceptive pain and ten-
derness of (pericranial) muscles. In contrast, the neuritis model 
(34, 78) hypothesized an inflammation of a peripheral nerve that 
produced a TrP as the result of ectopic impulses coming from 
the site of inflammation, while muscle pain and tenderness are 
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described in terms of secondary hyperalgesia arising from the 
inflamed nerve. Considering primary headaches as separated 
entities, in case of TTH it has been proposed that the transforma-
tion from infrequent to chronic TTH is the result of the sensitiza-
tion of the TNC (14, 43, 79) due to the presence of TrP according 
to the integrated TrP hypothesis. Thus, this mechanism is likely 
to explain the greater reduction of frequency and intensity of 
attacks for patients with TTH found in the present manuscript, 
but it is contradicted to some extent by the lack of reduction of 
duration of attacks as the de-sensitization of the TNC would 
also reduce the length of an attack likewise. In case of MH, it has 
been proposed according to the integrated TrP hypothesis that 
the nociceptive inputs arising from active TrPs may excite the 
TNC, activate the already sensitized trigemino-vascular system 
(16) and, consequently, promote a migraine attack (44). This 
mechanism may explain why frequency decreases to a little extent 
also in the MH group even though the reduction of intensity and 
duration of attacks seems paradoxical as the pain is driven by the 
trigemino-vascular system and not by the presence of TrPs which, 
constituting a precipitating factors, should influence only the 
frequency of the attacks. Furthermore, considering the vascular 
genesis proposed for TTH (15), the integrated TrP hypothesis is 
supported by the reduction of frequency of attacks with subtle 
effects on the reduction of duration of attacks, even though we 
should not expect a reduction of intensity of headache pain as 
previously described for MH.
The neuritis model better supports our results in terms 
of pooled groups and analyzed as subgroups. In fact, as MH 
may be the result of the central sensitization of the TNC due 
to inflammation of peripheral nerves it is possible that a TrPs 
treatment reduces frequency, intensity, and duration of MH 
attacks. Furthermore, supposing that the duration of attacks is 
driven by the central sensitization of the TNC according to the 
continuum model (30), the neuritis model may also explain why 
in TTH the duration of attacks is not reduced as TTH represents 
a mild form of migraine in which attacks are less intense and 
last less. However, the mechanisms of action of TrPs treatment 
with a neuritis model perspective remains unclear as TrPs are 
seen as the result of ectopic stimuli arising from the nerves and a 
link between muscular treatment and resolution of nerve inflam-
mation has not been established yet apart from a reduction of 
mechanical forces on the nerves (80). Therefore, despite the 
proven effectiveness of the TrPs treatment on primary headaches, 
there is still the need to understand properly on which basis the 
manual TrPs treatment might work. For example, in one study 
(64) that delivered a sham treatment (detuned ultrasound) to the 
CG, an improvement was observed and this phenomenon pose 
several questions on which are the mechanisms underpinning 
the effectiveness of unblinded interventions, such as a placebo 
effect (81), as it may also activate cortical mechanisms of pain 
inhibition.
Our findings are in contrast with the result of a previous 
meta-analysis of Luedtke et  al. (56) that reported no effect of 
physiotherapy (based mainly on exercises, modalities, relaxation 
techniques, and education) versus various comparators (any type 
of placebo intervention, any other active intervention as well as 
waiting list or standard care) in terms of intensity, frequency, and 
duration outcomes on primary headaches (56); however, authors 
included only one study adopting the TrP therapy, also present in 
the present manuscript (74), and did not consider primary head-
aches as an homogeneous group. It is, therefore, possible that the 
lack of specificity of treatments different from the TrPs therapy 
did not aim at the sensitization of the TNC and this may explain 
the different results. Finally, our results are consistent with two 
reviews reporting that a combination of massage therapy and 
exercise has the same efficacy of prophylactic treatment in patient 
with CTTH (52) and with MH (53).
At this time, we were unable to identify the most effective tech-
nique among those proposed as the treatments were delivered 
with a great variability in terms of techniques used (compression 
techniques, myofascial release, muscle energy, soft tissues, and 
positional release techniques) and their dosage (time of indi-
vidual session, length of the treatment session, and the number of 
treatment per week); often the treatment protocols involved the 
use of more than a single technique. Furthermore, as the results 
were presented for MH and TTH merging episodic and chronic 
conditions, it was impossible to establish whether the effective-
ness of TrPs manual treatment may differ among conditions with 
different frequency of attacks. Despite these considerations, both 
in TTH and MH, the muscles treated were mainly the sterno-
cleidomastoideus, the upper trapezius, and the sub-occipitals 
and this could represent an important clinical indication for the 
operators.
Regarding pain reduction, although we have normalized the 
different scales to a single 0–100 scale, standardized unidimen-
sional pain scales should be used in future studies to determine 
whether the obtained reduction has a clinical relevance and not 
merely a statistical significance.
Despite planned, we were not able to report on the additional 
negative effects of the manual treatment of TrPs as the included 
studies did not report them. The additional positive effects were 
reported sparsely in the retrieved studies, therefore, and they were 
grouped in three macro categories called medicine consumption, 
quality of life, and effects on TrPs. The evidences on reduction of 
medicine consumption were controversial: in patients with TTH 
one study reported a reduction (74, 76) and others no difference 
in the number of tablets taken (64, 75), while in MH the manual 
TrPs treatment may support the pharmacological treatment (75). 
The same doubts were present on the quality of life category, as 
there were no differences in questionnaires measuring general 
health (75) in patient with TTH and anxiety and stress in patients 
with MH (67). An effect was found for questionnaires like the HDI 
and the HIT-6 (60, 64). Furthermore, despite a similar amount of 
sleeping hours, the quality of sleep improved in patients with MH 
(67). For the category effects on TrPs, a reduction of the number 
of active TrPs (75) and an increased pressure pain threshold were 
found in the muscles manually treated (64, 74).
Our findings must be interpreted with caution for the weak-
ness of the level of the evidence mainly due to the high RoB within 
studies and imprecision in results. Moreover, as the majority of 
the included studies had short-term follow-up, the long-term 
effect of TrPs manual treatment still needs to be established.
Performance and detection bias mainly constituted the 
judgment of high RoB across our trials downgrading the level 
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of evidence. Performance bias refers to systematic differences 
between groups in the care that is provided, or in exposure to 
factors other than the interventions of interest. Detection bias 
refers to systematic differences between groups in how out-
comes are determined (82). Blinding may reduce the risk that 
knowledge of which intervention was received, rather than the 
intervention itself, affects outcomes: it is a cornerstone of treat-
ment evaluation (83). Lack of blinding in RCTs has been shown 
to be associated with more exaggerated estimated intervention 
effects (84, 85). As expected, blinding of participants and pro-
viders was not present in all of our studies. In fact, blinding is 
more difficult to obtain in trials assessing non-pharmacological 
treatments, such as manual therapy. Therefore, researchers and 
readers must be aware of existing methods of blinding to be 
able to appraise the feasibility of blinding in a trial (83). For 
example, in manual therapy, patients could be blind to the 
active placebo therapy (83). However, if blinding is not possible 
researchers could standardize the treatment of the groups (apart 
from the intervention), consider an expertise-based trial design, 
use objective, and reliable outcomes if possible, and consider 
duplicate assessment (86). Nevertheless, when performance 
bias could not be avoided, at least blinding of assessors must be 
performed to ensure unbiased ascertainment of outcomes (87), 
mostly in subjective outcomes (84). Furthermore, considering 
the chronicity of primary headaches, the use of single case 
research design (SCR) to demonstrate treatment efficacy may 
also have a role (88). SCR has been considered as a possible 
method for the scientific evaluation of manual therapies (89) 
and several reports argue for this (90–92).
The second important reason for downgrading the level of 
evidence was imprecision in results mainly due to an unwar-
ranted paucity of participants included in the comparisons (mean 
of 45 subjects) that avoid to reach the optimal information size. 
Considering the high prevalence of headache and the largely 
adopted manual treatments, physical therapists and research-
ers should demonstrate that manual therapy represents a valid 
option (for example, no risk of toxicity or overuse of medica-
tions) in the spectrum of headache therapies. Only if they invest 
more efforts to enhance powered and well-designed RCTs, the 
interventions can be universally accepted by the evidence-based 
medicine. Therefore, we call for a launch of further well-designed 
trials. Particularly, we encourage clinicians, researchers, and all 
stakeholders to promote multicenter trials focused in manual 
therapy treatment for TTH and/or MG. Multicenter trials should 
be based on a powered sample size calculation needed to reach 
the clinical relevance of the manual treatment versus the minimal 
intervention. The RoB should be minimized at least through the 
blinding of assessment. Moreover, a trial sequential analysis could 
be proposed in order to aim at the firm evidence, confirming or 
confuting our preliminary results.
LimitatiONS
The present review has some limitations that need to be addressed. 
Because we did not attempt to identify unpublished RCTs and 
our inclusion criteria were limited to only three languages, a 
publication bias could have occurred. The high variability of 
the delivered treatments prevented us from the identification 
of the most effective technique among those proposed. Even if 
epidemiological studies have determined that women are more 
likely to suffer from TTH and that female gender constitutes a 
risk factor for this disease (93), the higher prevalence of women 
in the TTH subgroup could make the results less applicable to the 
general population.
cONcLUSiON
There was very low evidence that manual TrPs treatment of the 
head and neck muscles may constitute a useful treatment to 
reduce frequency, intensity, and duration of attack in patients 
with TTH and MH. The included studies did not report any 
additional negative effects, while positive effects regarding 
reduction of medicine consumption were controversial.
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